Can quetiapine (Seroquel) 250 mg cause tremor?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Quetiapine (Seroquel) 250 mg Cause Tremor?

Yes, quetiapine 250 mg can definitely cause tremor as a recognized adverse effect, occurring through multiple mechanisms including extrapyramidal symptoms and drug-induced Parkinsonism.

Mechanism and Incidence

Quetiapine causes tremor through several pathways:

  • Extrapyramidal symptoms (EPS): Quetiapine, despite being an atypical antipsychotic, retains dopamine D2 receptor antagonism that can produce tremor as part of drug-induced Parkinsonism 1. The guidelines specifically identify tremor as part of the Parkinsonian syndrome triad alongside rigidity and muscle stiffness 1.

  • Direct adverse effect: The FDA label explicitly lists tremor as a common adverse reaction occurring in patients treated with quetiapine 2. In clinical trials, tremor was reported in multiple patient populations receiving quetiapine.

Clinical Evidence from FDA Data

According to the official FDA labeling 2:

  • Tremor appears as a documented adverse reaction in quetiapine-treated patients across multiple indications
  • The incidence varies by population and dose, but tremor is consistently reported
  • At 250 mg daily, you are in the therapeutic range where these effects can manifest

In pediatric populations 2, tremor combined with other EPS symptoms (akathisia, extrapyramidal disorder) occurred in 3-5% of patients, demonstrating that even "atypical" antipsychotics like quetiapine retain EPS liability.

Dose Considerations

At 250 mg daily, several factors increase tremor risk:

  • Moderate therapeutic dose: This falls within the range where EPS can emerge, though quetiapine generally has lower EPS risk than typical antipsychotics 3
  • Individual susceptibility: Older patients, those with pre-existing movement disorders, or concurrent use of other dopamine antagonists significantly increase risk 1, 4
  • Polypharmacy effects: Combining quetiapine with other medications that affect dopamine (metoclopramide, other antipsychotics) dramatically increases EPS risk 4, 5

Comparative Risk Profile

Quetiapine causes less tremor than typical antipsychotics but more than some other atypicals 3:

  • Quetiapine is noted as "less likely to cause EPSEs than another atypical AP" 3
  • However, it still carries meaningful risk, particularly at doses ≥200 mg daily
  • Research confirms tremor as one of the most common potentially EPS-associated adverse events with quetiapine 6

Clinical Presentation

When tremor occurs with quetiapine, expect:

  • Parkinsonian-type tremor: Rest tremor, often with cogwheel rigidity 1
  • Timing: Can occur early in treatment or after dose increases 1
  • Associated symptoms: May present with other EPS features including akathisia (restlessness), muscle rigidity, or bradykinesia 7, 4

Important Caveats

Drug interactions amplify risk: A case report 4 documented prolonged EPS including tremor from low-dose olanzapine (similar atypical antipsychotic) combined with metoclopramide. The same principle applies to quetiapine—any concurrent dopamine antagonist (antiemetics like metoclopramide, prochlorperazine, or other antipsychotics) substantially increases tremor risk.

Persistent tremor possible: While most drug-induced tremor resolves after discontinuation, some patients develop persistent "tardive tremor" 5. This is more common with prolonged use and higher cumulative exposure.

Paradoxical use: Interestingly, one small study 8 explored quetiapine for treating essential tremor, with mixed results—some patients actually worsened, highlighting individual variability in response.

Management Approach

If tremor develops on quetiapine 250 mg:

  1. Confirm drug-induced etiology: Rule out other causes (essential tremor, Parkinson's disease, metabolic abnormalities)
  2. Review all medications: Identify and eliminate other dopamine antagonists or tremor-inducing drugs 5
  3. Consider dose reduction: Lower doses may reduce EPS while maintaining therapeutic benefit
  4. Switch if necessary: Consider alternatives with lower EPS profiles (quetiapine already has relatively low risk, so switching to aripiprazole or clozapine might be considered) 3, 9
  5. Avoid routine anticholinergics: Guidelines 1 suggest managing by adjusting the antipsychotic rather than adding anticholinergics long-term

Bottom Line

Quetiapine 250 mg carries a well-documented risk of causing tremor through both EPS mechanisms and direct adverse effects 1, 2. While the risk is lower than with typical antipsychotics, it remains clinically significant, particularly in older adults, with polypharmacy, or at higher doses. Monitor patients for tremor development and be prepared to adjust therapy accordingly.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.